Ontogeny and sorafenib metabolism.
Article Details
- CitationCopy to clipboard
Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, Baker SD
Ontogeny and sorafenib metabolism.
Clin Cancer Res. 2012 Oct 15;18(20):5788-95. doi: 10.1158/1078-0432.CCR-12-1967. Epub 2012 Aug 27.
- PubMed ID
- 22927483 [ View in PubMed]
- Abstract
PURPOSE: To investigate the role of ontogeny in sorafenib metabolism to the equipotent active metabolite sorafenib N-oxide. EXPERIMENTAL DESIGN: Steady-state pharmacokinetic studies of sorafenib and metabolites were conducted in 30 children and young adults (17 males; median age, 9.5 years) receiving sorafenib 150 mg/m(2) or 200 mg/m(2) twice daily. Sorafenib metabolism was evaluated in vitro at 10 mumol/L using a panel of purified human cytochrome P450 (CYP) enzymes. Sorafenib metabolism and CYP3A4 expression was evaluated in 52 human liver samples from donors of
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Sorafenib Cytochrome P450 1A2 Protein Humans UnknownSubstrateDetails